Voyager Therapeutics Presents Three-Month GLP Toxicology Data for VY1706
Voyager Therapeutics presented three-month good laboratory practice, or GLP, toxicology data for VY1706, the Company's investigational tau silencing gene therapy for Alzheimer's disease, or AD, in a late-breaking presentation at the American Society of Gene & Cell Therapy's 2026 Annual Meeting in Boston, May 11-15. Data presented showed that VY1706 was well tolerated, with no adverse clinical pathology or histopathological findings up to the highest dose tested, and reduced tau protein up to 64% in key brain regions of non-human primates, or NHPs, at 13 weeks following a single IV dose. Voyager's FDA investigational new drug, or IND, application process for VY1706 is on track for Q2 2026 to support projected first-in-human dosing in AD patients in H2 2026. Intravenous delivery of VY1706, a CNS penetrant AAV gene therapy for Alzheimer's disease, demonstrates compelling pharmacology and safety in a 3-month GLP toxicology study in NHPs. VY1706 delivered a potent vectorized MAPT siRNA with broad central nervous system, or CNS, distribution via a single IV dose, using ALPL as its primary blood-brain barrier, or BBB, receptor. 3-month GLP toxicology data for VY1706 demonstrated a favorable tolerability profile with no adverse findings up to the highest dose tested. Treatment with VY1706 resulted in dose-dependent reductions of up to 51-75% MAPT mRNA and 48-64% tau protein in key brain regions at 13 weeks in NHPs. Data from Voyager's seven additional oral and poster presentations at ASGCT demonstrate continued capsid innovation via muscular and neuromuscular targeting, immune evasion, and manufacturability. Directed evolution of muscular and neuromuscular capsid variants in both mice and non-human primates. Voyager leveraged its TRACER platform to develop novel AAV9-based capsids with significantly increased muscle tropism over AAV9 in both mice and NHPs. In mice, the top muscle-targeted capsid achieved 100X increased expression over AAV9 in skeletal muscle and 10X increased expression in heart muscle. In NHPs, the top muscle-targeted capsid achieved 25-30X increased expression over AAV9 in skeletal muscle and 13X increased expression in heart muscle. Voyager generated neuromuscular capsids with features of both muscle and brain capsids, achieving comparable transduction levels to top muscle and brain capsids in NHPs while demonstrating significantly reduced liver exposure relative to AAV9. Intravenous delivery of a bi-functional AAV gene therapy to reduce endogenous ApoE4 and express ApoE2 in ApoE4 humanized mice. A novel BBB-penetrant capsid delivering a bi-functional payload significantly reduced endogenous ApoE4 while achieving expression of ApoE2 at physiological levels following single dose IV-delivery in murine studies. Engineering an AAV9-derived muscle-tropic capsid to evade pre-existing human neutralizing antibodies. A next-generation "stealth" capsid was able to evade pre-existing neutralizing antibodies while retaining muscle tropism, potentially increasing the number of patients eligible to receive muscle-targeted AAV gene therapies. Leveraging artificial intelligence to design AAV mutant capsids optimized for antibody evasion. Novel AAV capsid variants, generated using advanced AI models, showed improvements in antibody evasion, while maintaining favorable manufacturing and CNS-transduction properties. Exploiting an AAV capsid specific receptor to develop stable cell lines for transduction based assays for gene therapies. Cell lines overexpressing a receptor associated with Voyager's TRACER capsids overcome the challenge of lower transduction efficiency observed for engineered capsids in cell-based assays. Evaluating affinity chromatography media for capture of novel blood-brain-barrier penetrant AAV capsids. Optimized transfection platform with improved productivity and transgene packaging for scalable rAAV production.
Trade with 70% Backtested Accuracy
Analyst Views on VYGR
About VYGR
About the author

- Clinical Application Progress: Voyager Therapeutics is on track to complete the IND application for VY1706 by Q2 2026, supporting the first-in-human trial for Alzheimer's patients in H2 2026, marking a significant milestone in the treatment of neurological diseases.
- Safety Data: At the ASGCT annual meeting, GLP toxicology data for VY1706 showed no adverse clinical or histopathological findings at the highest tested dose (5E13 vg/kg), with tau protein reductions of up to 64% in non-human primates, indicating good tolerability and potential therapeutic effects.
- Drug Delivery Innovation: VY1706 demonstrated broad central nervous system distribution via a single IV dose, achieving dose-dependent reductions of MAPT mRNA and tau protein by 51-75% and 48-64%, respectively, paving the way for new possibilities in gene therapy for Alzheimer's disease.
- Platform Advantages: Voyager's TRACER™ platform excels in developing novel AAV capsids that effectively evade human neutralizing antibodies while enhancing muscle targeting capabilities, which is expected to expand the eligible patient population and further drive clinical applications of gene therapies.
- Revenue and Loss: In Q1 2026, Voyager Therapeutics reported revenue of $2.6 million and a net loss of $27.9 million, indicating significant challenges in profitability despite a slight increase in revenue.
- R&D Expense Reduction: R&D expenses for Q1 were $24.6 million, down from $31.5 million in Q1 2025, primarily due to cost-cutting and efficiency initiatives, although increased costs related to the tau silencing gene therapy program suggest strategic shifts in R&D focus.
- Decrease in Administrative Costs: General and administrative expenses decreased to $8.3 million in Q1 2026 from $9.6 million in the previous year, reflecting effective cost control measures taken by the company to address ongoing financial pressures.
- Cash Flow Position: As of March 31, 2026, Voyager had $171.7 million in cash, cash equivalents, and marketable securities, which is expected to be sufficient to meet operating and capital expenditure needs through 2028, indicating a degree of financial stability.
- Orphan Drug Status: The FDA has granted orphan drug designation to Neurocrine Biosciences' NBIB-223 (frataxin), which allows for up to seven years of market exclusivity post-approval, significantly enhancing its commercial potential.
- Tax Incentives: With orphan drug status, NBIB-223 will benefit from tax credits for clinical trial expenses, reducing R&D costs and thereby strengthening Neurocrine's competitive position in the Friedreich ataxia treatment landscape.
- Gene Therapy Innovation: NBIB-223 is a gene therapy that employs Voyager Therapeutics' modified AAV capsid to deliver the frataxin gene throughout the body, showcasing Neurocrine's commitment to cutting-edge medical technology and innovation.
- Market Competition: The only approved treatment for Friedreich ataxia is Biogen's Skyclarys (omaveloxolone), and the introduction of NBIB-223 will provide patients with more options while potentially challenging Biogen's market share.
- Preclinical Data Showcase: VY1706 demonstrates compelling pharmacology and safety in a three-month GLP toxicology study in non-human primates, indicating its potential as a treatment for Alzheimer's disease, with clinical trials expected to commence in the second half of 2026, potentially offering new therapeutic options for patients.
- Technological Innovation: The novel AAV capsids developed through Voyager's TRACER platform effectively penetrate the blood-brain barrier and achieve widespread drug expression, enhancing treatment capabilities for Alzheimer's while opening new avenues for other neurological disorders.
- Immune Evasion Strategy: The application of new technologies allows VY1706 to expand the eligible patient population while minimizing immune responses, which not only improves treatment efficacy but also potentially reduces side effects, increasing patient acceptance.
- Future Development Plans: Voyager aims to submit an IND application in Q2 2026, marking a significant advancement in its Alzheimer's program, which is expected to create new market opportunities and bolster investor confidence.
- Executive Changes: Voyager Therapeutics CFO Nathan Jorgensen announced his resignation effective May 8, 2026, to pursue a new opportunity, leading to potential instability in financial leadership that may affect investor confidence.
- New Financial Leadership: The Board has appointed current COO and CBO Robin Swartz as the new Principal Financial Officer and Treasurer effective immediately, ensuring continuity in financial leadership aimed at stabilizing company operations.
- Enhanced Accounting Oversight: Amy Quinlan has been named Principal Accounting Officer, strengthening the company's accounting oversight, indicating a commitment to financial transparency and compliance.
- Stock Price Reaction: Following the executive changes announcement, Voyager Therapeutics' stock closed approximately 2.60% lower at around $4.12, reflecting market caution regarding the leadership transition.
- Earnings Highlights: Voyager Therapeutics reported a Q4 GAAP EPS of -$0.46, beating expectations by $0.07, indicating an improving trend in the company's profitability metrics.
- Collaboration Revenue Surge: The company achieved collaboration revenue of $15.34 million, representing a 144.3% year-over-year increase, which not only exceeded market expectations by $4.85 million but also reflects the success of its strategic partnerships and strong market demand.
- Cash Position: As of December 31, 2025, Voyager's cash, cash equivalents, and marketable securities totaled $201.7 million, ensuring sufficient funding for future R&D and operational activities.
- Market Outlook: With significant growth in collaboration revenue and a robust cash position, Voyager Therapeutics is poised to enhance its competitive edge in the biopharmaceutical sector, supporting the realization of its long-term strategic objectives.









